Hôpital Pontchaillou-CHU Rennes
- Address
- lock Available on a paid plan
Digestive System Diseases
The department is conducting studies on colon carcinoma to test innovative treatment combinations and refine post‑surgical monitoring.
- Evaluation of adjuvant chemotherapy guided by circulating tumor DNA
- Combination of targeted agents with bevacizumab for high‑risk colorectal cancer
- Immunotherapy assessment in patients with dMMR metastatic colorectal tumors
- Exploration of biomarkers for early detection of disease recurrence
At Hôpital Pontchaillou‑CHU Rennes eight trials involve 162 investigators, advancing therapeutic options for digestive system malignancies.
Hemic and Lymphatic Diseases
Ongoing research evaluates first‑line strategies for high‑risk large B‑cell lymphoma, including diffuse large B‑cell lymphoma and high‑grade subtypes.
- Comparison of CAR‑T cell therapy with standard of care
- Assessment of event‑free survival as a primary endpoint
- Safety profiling of novel combination regimens
- Optimization of treatment sequencing for aggressive lymphomas
The site’s multidisciplinary team leverages its extensive investigator network to improve outcomes for patients with hematologic malignancies.
Neoplasms
A targeted study investigates the efficacy of a novel agent in ROS1‑positive non‑small cell lung cancer, aiming to increase response rates.
- Development of kinase‑inhibitor therapies for molecularly defined lung tumors
- Measurement of objective response using standardized criteria
- Monitoring of patient‑reported outcomes during treatment
- Integration of precision medicine approaches across tumor types
These trials contribute to the broader oncology portfolio at the Rennes research center, supporting personalized cancer care.
Nervous System Diseases
Researchers are testing a new compound for early Parkinson’s disease to determine its ability to slow motor symptom progression.
- Evaluation of disease‑modifying agents using the MDS‑UPDRS scale
- Safety and tolerability assessment in adult participants
- Long‑term follow‑up of functional outcomes
- Exploration of biomarkers predictive of therapeutic response
By integrating neurology expertise, the site aims to bring innovative therapies to patients with neurodegenerative disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 20 therapeutic areas and 15 of 187 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 182 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.6trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital Pontchaillou-CHU Rennes
lock Showing 1 of 105 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 187 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 9 | Unknown | 2023-01-16 | 2025-11-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.